Related Experiment Video
Updated: Jul 10, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
The endocannabinoid system and Alzheimer's disease
Cristina Benito1, Estefanía Núñez, María Ruth Pazos
1Laboratorio de Apoyo a la Investigación, Fundación Hospital Alcorcón, C/ Budapest 1, 28922 Alcorcón, Madrid, Spain.
Molecular Neurobiology
|October 24, 2007
Summary
The endocannabinoid system (ECS) shows potential for treating neurodegenerative diseases like Alzheimer's. Modulating the ECS, particularly through cannabinoid receptors, may offer beneficial effects.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- The endocannabinoid system (ECS) plays a crucial role in the central nervous system (CNS).
- Cannabinoid receptors (CB1 and CB2) and enzymes like FAAH are key components of the ECS.
- The ECS is increasingly recognized for its involvement in neurodegenerative diseases.
Purpose of the Study:
- To explore the diverse roles of the ECS in neurodegenerative conditions.
- To evaluate the potential of modulating the ECS as a therapeutic strategy for Alzheimer's disease (AD).
Main Methods:
- Review of in vitro studies.
- Analysis of data from animal models of AD.
- Examination of human samples.
Main Results:
- Cannabinoid CB1 receptors are highly distributed in the CNS, influencing pathophysiological conditions.
- CB2 receptors and FAAH are identified as promising pharmacological targets.
- Preliminary data suggest that activating the ECS may benefit Alzheimer's disease progression.
Conclusions:
- Modulation of the endocannabinoid system represents a novel therapeutic approach for Alzheimer's disease.
- Activating the ECS, via agonists or enhancing endogenous tone, shows potential for beneficial effects in AD.
- Further research into the ECS is warranted for neurodegenerative disease treatment.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...